The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?

Author:

Docherty Kieran F1,Bayes-Genis Antoni2,Butler Javed34,Coats Andrew J S5,Drazner Mark H6,Joyce Emer78,Lam Carolyn S P9

Affiliation:

1. British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place , Glasgow G12 8TA , UK

2. Institut del Cor, Hospital Universitari Germans Trias i Pujol, CIBERCV, 08916 Badalona , Barcelona , Spain

3. Baylor Scott and White Research Institute , 3434 Live Oak St Ste 501, Dallas, TX 75204 , USA

4. Department of Medicine, University of Mississippi Medical Center, 2500 N State St , Jackson, MS 39216 , USA

5. Warwick Medical School, University of Warwick , Coventry, CV4 7HL , UK

6. University of Texas Southwestern Medical Center, Department of Internal Medicine, Division of Cardiology, 5323 Harry Hines Blvd. , Dallas, TX 75390-9254 , USA

7. Department of Cardiology, Mater Misericordiae University Hospital , Eccles St, Dublin 7, D07 R2WY , Ireland

8. School of Medicine, University College Dublin, Bellfield , Dublin 4 , Ireland

9. National Heart Centre Singapore, Duke-National University of Singapore , 5 Hospital Dr, Singapore 169609 , Singapore

Abstract

Abstract The syndrome of heart failure (HF) has historically been dichotomized based on clinical trial inclusion criteria into patients with a reduced or preserved left ventricular ejection fraction (LVEF) using a cut-off of above or below 40%. The majority of trial evidence for the benefits of disease-modifying pharmacological therapy has been in patients with HF with reduced ejection fraction (HFrEF), i.e. those with an LVEF ≤40%. Recently, the sodium-glucose co-transporter 2 inhibitors empagliflozin and dapagliflozin have been shown to be the first drugs to improve outcomes in HF across the full spectrum of LVEF. There is, however, growing evidence that the benefits of many of the neurohumoral modulators shown to be beneficial in patients with HFrEF may extend to those with a higher LVEF above 40% but still below the normal range, i.e. HF with mildly reduced ejection fraction (HFmrEF). Whether the benefits of some of these medications also extend to patients with HF and preserved ejection fraction (HFpEF) is an area of ongoing debate. This article will review the evidence for HF treatments across the full spectrum of LVEF, provide an overview of recently updated clinical practice guidelines, and address the question whether it may now be time to treat HF with some therapies regardless of ejection fraction.

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3